The Latest Cardiac and Vascular News
PRINCETON, N.J., Oct. 7, 2022 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced today that its Chief Financial Officer, Kathleen P. Bloch, MBA, CPA, plans to retire on March 31, 2023 at age 68, […]
PRINCETON, N.J., Aug. 17, 2022 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that the Israeli Ministry of Health (MoH) has approved national reimbursement for CytoSorb® in certain cardiac surgery indications that […]
PRINCETON, N.J., Aug. 2, 2022 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today reported unaudited financial and operating results for the quarter ended June 30, 2022. Second Quarter 2022 Financial Results Total Q2 […]
The 2022 CytoSorb World Users’ Meeting focuses on groundbreaking new applications of the adsorption technology to celebrate the 10th anniversary of commercialization PRINCETON, N.J. and BERLIN, July 1, 2022 /PRNewswire/ — Under the theme “We Are Changing Medicine: CytoSorb Therapy – From the Past to the Future,” CytoSorbents Corporation (NASDAQ: CTSO) is bringing together nearly 300 of the […]
Q1 2022 total revenue was $8.7 million, including product sales of $7.9 million. Core non-COVID-19 product sales were an estimated $7.6 million, and on a constant currency basis were comparable to core product sales a year ago. Product gross margins were 80%. MONMOUTH JUNCTION, N.J., May 3, 2022 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the […]
MONMOUTH JUNCTION, N.J., May 2, 2022 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced that the Company has been awarded a new preferred supplier agreement for CytoSorb® with the Asklepios Group (Asklepios), one of the largest private […]
MONMOUTH JUNCTION, N.J., April 29, 2022 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced today that the first patient has been enrolled in the Safe and Timely Antithrombotic Removal-Direct Oral Anticoagulants (STAR-D) double-blind, randomized, controlled clinical trial designed to […]
MONMOUTH JUNCTION, N.J., April 14, 2022 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that it has registered a new subsidiary, CytoSorbents Medical UK Limited, with plans to establish a direct sales presence within the United Kingdom (UK) and Ireland. CytoSorbents previously sold […]
MONMOUTH JUNCTION, N.J., April 7, 2022 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it has received approximately $740,000, net of transactions costs, in cash proceeds from the sale of its 2020 Net Operating Loss (NOL) and […]
MONMOUTH JUNCTION, N.J. , April 5, 2022 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces the appointment of Ms. Jiny Kim, MBA to CytoSorbents’ Board of Directors as a new independent director, effective immediately, for a term expiring at […]
